Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-04-069: In Vivo Cellular and Molecular Imaging Centers (ICMICS)

    • Release Date: February 27, 2004
    • Application Receipt Date: July 22, 2004; July 21, 2005
    • Contacts:

      Anne E. Menkens, Ph.D. (am187k@nih.gov) at 301-435-9024

    The Cancer Imaging Program, Division of Cancer Diagnosis and Treatment of the National Cancer Institute (NCI), invites applications for new or competing P50 Research Center Grants for In Vivo Cellular and Molecular Imaging Centers (ICMICs). This initiative is designed to capitalize on the extraordinary opportunity for molecular imaging to have an impact on the diagnosis and treatment of cancer patients non-invasively and quantitatively. Molecular imaging technologies can provide valuable laboratory tools for the interrogation of biological pathways relevant to cancer, as well as to provide imaging agents and technologies that will be directly utilized in the clinic. The 5-year P50 ICMIC grants described in this PAR are designed to bring together interdisciplinary scientific teams to lead the nation in cutting-edge cancer molecular imaging research with clinical relevance, provide unique core facilities to support oncology imaging research, provide flexibility to respond to exciting pilot research opportunities, and provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging. The P50 mechanism will promote coordination, interrelationships and scientific synergy among the research components and resources, leading to a highly integrated imaging center.

    • Letter of Intent Receipt Date(s): June 22, 2004; June 21, 2005

    See full description in NIH Guide:PAR-04-069

  • PA-04-063: An SBIR/STTR Initiative for Image-Guided Cancer Interventions

    • Release Date: February 17, 2004
    • Application Receipt Date: April 1, August 1, and December 1
    • Contacts:

      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

    The purpose of this Program Announcement (PA) is to support the development and clinical validation of systems for image-guided interventions (IGI) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multi-site clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

    • SBIR set-aside

    See full description in NIH Guide:PA-04-063

    What is SBIR?
    What is STTR?

  • RFA: CA-05-007: Application of Emerging Technologies for Cancer Research (SBIR/STTR)

    • Release Date: January 07, 2004
    • Application Receipt Date: March 10, 2004; June 17, 2004; October 18, 2004
    • Contacts:

      Barbara Y. Croft, Ph.D. (bc129b@nih.gov) at 301-496-9531

    The NCI invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements, as well as be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus.

    • Letter of Intent Receipt Date(s): February 10, 2004; May 17, 2004; September 17, 2004

    See full description in NIH Guide: RFA: CA-05-007

  • NCI RFA: CA-05-006: Innovative Technologies for Molecular Analysis of Cancer (SBIR/STTR)

    • Release Date: January 07, 2004
    • Application Receipt Date: March 10, 2004; June 17, 2004; October 18, 2004
    • Contacts:

      Barbara Y. Croft, Ph.D. (bc129b@nih.gov) at 301-496-9531

    The NCI invites applications for research projects proposing the development of highly innovative cancer relevant technologies, encompassing methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Technology is distinct from resources such as databases, reagents, and tissue repositories.

    • Letter of Intent Receipt Date(s): February 10, 2004; May 17, 2004; September 17, 2004

    See full description in NIH Guide:RFA: CA-05-006

  • PA-04-045: In Vivo Cancer Imaging Exploratory/Developmental Grants (R21)

    • Release Date: December 24, 2003
    • Application Receipt Date: February 1, June 1, and October 1
    • Contacts:

      Anne E. Menkens, Ph.D. (am187k@nih.gov) at 301-435-9024

    The Cancer Imaging Program (CIP) of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) applications that articulate exploratory/developmental research focused on in vivo cancer imaging. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial development and/or feasibility testing of high impact concepts. Topics considered responsive to this Program Announcement will cover the entire spectrum of in vivo cancer imaging research, from basic discovery of new cancer imaging agents and technologies, through pre-clinical testing and validation, to the early feasibility testing of those novel agents and technologies in small clinical trials. The applicant may request a project period of up to two years with a combined budget for direct costs of up $275,000 for the two year period.

    • No set-aside

    See full description in NIH Guide:PA-04-045

  • PA-04-046: Clinical Cancer Therapy and Prevention Research

    • Release Date: December 24, 2003
    • Application Receipt Date: February 1, June 1, and October 1
    • Contacts:

      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

    The NCI is seeking R01 applications to conduct translational, clinical, therapeutic, and preventive studies/trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer biology and the development of new anti-cancer agents into innovative cancer intervention studies/trials. The overall aims of this renewed PA are two-fold: (1) to stimulate development of innovative therapeutic/preventive clinical trials with or without laboratory correlative studies (2) to support innovative correlative laboratory studies linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

    • No set-aside

    See full description in NIH Guide:PA-04-046

  • NCI/NIH RFA: CA-04-011: Small Animal Imaging Resource Programs

    • Release Date: October 02, 2003
    • Application Receipt Date: December 18, 2003
    • Contacts:

      Barbara Y. Croft, Ph.D. (bc129b@nih.gov) at 301-496-9531

    The National Cancer Institute (NCI) invites applications from extramural investigators for Small Animal Imaging Resource Programs (SAIRPs). These grants will support (a) shared imaging research resources to be used by cancer investigators, (b) research related to small animal imaging technology, and (c) training of both professional and technical support personnel interested in the science and techniques of small animal imaging.

    • Letter of Intent Receipt Date(s): November 18, 2003

    See full description in NIH Guide:NCI/NIH RFA: CA-04-011

  • PAR-03-157: Industry-Academic Partnerships for Development of Biomedical Imaging Systems and Methods that are Cancer Specific (R21)

    • Release Date: July 29, 2003
    • Application Receipt Date: November 19, 2003; November 17, 2004
    • Contacts:

      Guoying Liu, Ph.D. (liug@mail.nih.gov) at 301-594-5220

    The National Cancer Institute (NCI) invites applications for the pursuit of industry-academic partnerships for development of biomedical imaging systems and methods that are cancer specific. Support for the exchange of scientists between industry and academia can be requested under this initiative.

    The goals of this initiative are to

    1) Provide grants to help establish and/or expand industry-academic partnerships for development of biomedical imaging systems and methods that are cancer specific whether or not preliminary data or a history of prior collaborations have been established;

    2) Support partnerships and pilot projects that may result in commercialization of imaging technologies;

    3) Target partnerships that address high-risk/high-gain research and development of new approaches for early cancer detection, diagnosis, image-guided interventions, and assessment of drug therapy.

    • Letter of Intent Receipt Date(s): October 22, 2003; October 20, 2004

    See full description in NIH Guide: PAR-03-157

    What is the R21 grant mechanism?

  • PAR-03-124: Novel Technologies for In vivo Imaging (R21/R33)

    • Release Date: May 19, 2003
    • Application Receipt Date: July 21, 2003 and November 19, 2003
    • Contacts:

      Houston Baker, Ph.D. (bakerhou@mail.nih.gov)

    PAR-03-124 has been replaced by PA-04-095, which uses Regular Receipt Dates: June 1, October 1, and February 1.

    The National Cancer Institute (NCI) and the National Institute for Biomedical Imaging and Bioengineering (NIBIB) invite applications for the development and delivery of novel image acquisition or enhancement technology and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the proof of feasibility, development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and secondarily to facilitate limited evaluation studies to show proof of concept and functionality.

    • Letter of Intent Receipt Date(s): June 23, 2003 and October 22, 2003

    See full description in NIH Guide:PAR-03-124

    See full description in NIH Guide:PA-04-095

  • PAR-03-125: Novel Technologies for In vivo Imaging (SBIR/STTR)

    • Release Date: May 19, 2003
    • Application Receipt Date: July 21, 2003 and November 19, 2003
    • Contacts:

      Houston Baker, Ph.D. (bakerhou@mail.nih.gov)

    PAR-03-125 has been replaced by PA-04-094, which uses Regular Receipt Dates: August 1, December 1, and April 1.

    The National Cancer Institute (NCI), the National Institute of Environmental Health Sciences (NIEHS), the National Institute for Biomedical Imaging and Bioengineering (NIBIB) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications for the development and delivery of novel image acquisition or enhancement technology and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the proof of feasibility, development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions and treatment of various diseases, and secondarily to facilitate limited evaluation studies to show proof of concept and functionality.

    • Letter of Intent Receipt Date(s): June 23, 2003 and October 22, 2003

    See full description in NIH Guide:PAR-03-125

    See full description in NIH Guide:PA-04-094